HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
  1. Home
  2. /Compound

Aceclofenac

HCID 71771
NotesReactions
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
89796-99-6
Standard SMILES
O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
InChIKey
MNIPYSSQXLZQLJ-UHFFFAOYSA-N
Molecular formula
C16H13Cl2NO4
Average molar mass
354.2 g/mol
Monoisotopic mass
353.0221633

Overview

Aceclofenac is a monocarboxylic acid that is the carboxymethyl ester of diclofenac. A non-steroidal anti-inflammatory drug related to diclofenac, it is used in the management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is a dichlorobenzene, a monocarboxylic acid, a carboxylic ester, an amino acid and a secondary amino compound. It is functionally related to a diclofenac.

Names & identifiers

Preferred name
Aceclofenac
IUPAC
2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid
English name
Aceclofenac
Molecular formula
C16H13Cl2NO4
Molecular weight
354.18

Names & synonyms

Aceclofenac89796-99-6AceclofenacoAirtalAceclofenacumAceclofenac betadexBiofenacClanzaDTXSID7045522RPK779R03HCHEBI:311592-[(2,6-dichlorophenyl)amino]benzeneacetic acid carboxymethyl ester
Show more names
ZerodolPreservexAcelofenacAceclofenac-D4GerbinFalcolPR-82/3Tresquim
2-((2,6-dichlorophenyl)amino)phenylacetoxyacetic acidGlycolic Acid [o-(2,6-Dichloroanilino)phenyl]acetate EsterDTXCID50255222-((2,6-Dichlorophenyl)amino)benzeneacetic acid carboxymethyl ester2-[(2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetyl)oxy]acetic acid2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acid2-[(2',6'-dichlorophenyl)amino]phenylacetoxyacetic acidBeofenac

Database identifiers

CAS
89796-99-6
PubChem CID
71771
DTXSID
DTXSID7045522
ChEMBL
CHEMBL93645
ChEBI
CHEBI:31159

Properties

Computed structural properties

XLogP
4.3
Topological polar surface area
75.6 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
5
Rotatable bonds
7
Heavy atoms
23
Formal charge
0
Complexity
411

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP2.7
Solubility · 2 items

Insoluble

>53.1 [ug/mL] (The mean of the results at pH 7.4)

Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Inflammatory Agents, Non-Steroidal
Melting Point149-153

Physicochemical properties

Melting point
149 · 149-153°C
Boiling point
486 · 486.0±45.0 °C(Predicted)
Density
1.455 · 1.455±0.06 g/cm3(Predicted)
RTECS
1577900 · CY1577900
storage temp.
2 · 2-8°C
solubility
Soluble in DMSO
form
powder

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 1% (1 of 96) of reports.

Danger

H301 (99%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P264+P265, P270, P273, P280, P301+P316, P305+P351+P338, P321, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 96 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (99%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Aceclofenac

vLess-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
ridadr
UN 2811 6.1 / PGIII
hs_code
29224999
risk_code
25-36-50/53
Signal word
Danger
Symbol(GHS)
GHS06,GHS09
hazard_code
T,N

Chemistry & industry

Pharmacology

ATC Code · 5 items

M01AB16

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingIt is reported to be highly protein-bound (>99%).
Pharmacodynamics · 1 item

Aceclofenac is a NSAID that inhibits both isoforms of COX enzyme, a key enzyme involved in the inflammatory cascade. COX-1 enzyme is a constitutive enzyme involved in prostacyclin production and protective functions of gastric mucosa whereas COX-2 is an inducible enzyme involved in the production of inflammatory mediators in response to inflammatory stimuli. Aceclofenac displays more selectivity towards COX-2 (IC50 of 0.77uM) than COX-1 (IC50 of >100uM), which promotes its gastric tolerance compared to other NSAIDs. The primary metabolite, 4'-hydroxyaceclofenac, also minimally inhibits COX-2 with IC50 value of 36uM. Although the mode of action of aceclofenac is thought to mainly arise from the inhibition of synthesis of prostaglandins (PGE2), aceclofenac also inhibits the production of inflammatory cytokines, interleukins (IL-1β, IL-6), and tumor necrosis factors (TNF). It is also reported that aceclofenac also affects the cell adhesion molecules from neutrophils. Aceclofenac also targets the synthesis of glycosaminoglycan and mediates chrondroprotective effects.

Mechanism of Action · 1 item

Through COX-2 inhibition, aceclofenac downregulates the production of various inflammatory mediators including prostaglandin E2 (PGE2), IL-1β, and TNF from the arachidonic acid (AA) pathway. Inhibition of IL-6 is thought to be mediated by diclofenac converted from aceclofenac. Suppressed action of inflammatory cytokines decreases the production of reactive oxygen species. Aceclofenac is shown to decreased production of nitrous oxide in human articular chondrocytes. In addition, aceclofenac interferes with neutrophil adhesion to endothelium by decreasing the expression of L-selectin (CD62L), which is a cell adhesion molecule expressed on lymphocytes. Aceclofenac is proposed to stimulate the synthesis of glycosaminoglycan in human osteoarthritic cartilage which may be mediated through its inhibitory action on IL-1 production and activity. The chrondroprotective effects are generated by 4'-hydroxyaceclofenac which suppresses IL-1 mediated production of promatrix metalloproteinase-1 and metalloproteinase-3 and interferes with the release of proteoglycan from chrondrocytes.

Related reactions

0 records
New reaction record

No reaction records under the current filter.

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
UNII
RPK779R03H
EC Number
641-844-5
Nikkaji
J22.763C
pka
2.6 · 2.60±0.10(Predicted)
color
off-white to light tan
Water Solubility
32 mg/L · 32mg/L(32 ºC)
Merck
14 · 14,22
InChI
1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
InChIKey
MNIPYSSQXLZQLJ-UHFFFAOYSA-N
SMILES
OC(=O)COC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl
CAS DataBase Reference
89796 · 89796-99-6(CAS DataBase Reference)
FDA UNII
779 R03H · RPK779R03H
ATC code
1 AB16,M02AA25 · M01AB16,M02AA25
EPA Substance Registry System
2 · Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester (89796-99-6)
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Protein binding
99 % · >99%
Excreted unchanged in urine
66 · 66 (mainly as metabolites)
Volume of distribution
25 Litres · 25 Litres
Biological half-life
4 · 4 / Unchanged
Symbol(GHS)
6 · GHS06,GHS09
Signal word
Danger
Hazard statements
301 · H301-H319-H410
Precautionary statements
273 · P273-P301+P310+P330-P305+P351+P338
Hazard Codes
T,N
Risk Statements
25 · 25-36-50/53
Safety Statements
26 · 26-45-60-61
RIDADR
2811 · UN 2811 6.1 / PGIII
WGK Germany
3 · 3
HazardClass
6.1 · 6.1
PackingGroup
III
HS Code
29224999 · 29224999
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 OralAquatic · Acute Tox. 3 OralAquatic Acute 1Aquatic Chronic 1Eye Irrit. 2
safety_code
26-45-60-61
hazard_class
6.1
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301-H319-H410
Hazard Classifications
Acute Tox. 3 OralAquatic Acute 1Aquatic Chronic 1Eye Irrit. 2
Precautionary statements
P273-P301+P310+P330-P305+P351+P338
Biological Half-LifeThe mean plasma elimination half-life is approximately 4 hours.
Metabolism/Metabolites · 2 items

4'-hydroxyaceclofenac is the main metabolite detected in plasma however other minor metabolites include diclofenac, 5-hydroxyaceclofenac, 5-hydroxydiclofenac, and 4'-hydroxydiclofenac. It is probable that the metabolism of aceclofenac is mediated by CYP2C9.

Aceclofenac has known human metabolites that include diclofenac, 4'-hydroxy-aceclofenac, and 5-hydroxy-aceclofenac.

MeSH Pharmacological Classification · 1 item

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Absorption, Distribution and Excretion · 4 items

Aceclofenac is rapidly and completely absorbed from the gastrointestinal tract and circulates mainly as unchanged drug following oral administration. Peak plasma concentrations are reached around 1.25 to 3 hours post-ingestion, and the drug penetrates into the synovial fluid where the concentration may reach up to 60% of that in the plasma. There is no accumulation in regular dosing, with similar maximum plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) after single and multiple doses.

The main route of elimination is via the urine where the elimination accounts for 70-80% of clearance of the drug. Approximately two thirds of the administered dose is excreted via the urine, mainly as glucuronidated and hydroxylated forms of aceclofenac. About 20% of the dose is excreted into feces.

The volume of distribution is approximately 25 L.

The mean clearance rate is approximately 5 L/h.

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >250
Applications · 4 items

DescriptionAceclofenac is a non-steroidal anti-inflammatory drug (NSAIDs) that is commonly prescribed for people with painful rheumatic conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. The drug should not be given to children, breastfeeding mothers, and people with porphyria. Pregnant women should not also be given aceclofenac as they risk developing patent ductus arteriosus in the neonate.

DescriptionAceclofenac is a nonsteroidal antiinflammatory agent with analgesic and antipyretic properties. It is reported to be useful in the treatment of osteoarthritis, rheumatoid arthritis and pain associated with minor surgical procedures. Compared to ketoprofen in the treatment of rheumatoid arthritis, aceclofenac is substantially faster acting.

UsesLabeled Aceclofenac, intended for use as an internal standard for the quantification of Aceclofenac by GC- or LC-mass spectrometry.

UsesAceclofenac is a non-steroidal, anti-inflammatory drug (NSAID) with potent inhibitory activity in several models of inflammation. It is used for the treatment of osteoarthritis and rheumatoid arthritis. It is a Biopharmaceutics classification system class II (BCS class I) drug which has an intermediate half-life of 3-4h and undergoes substantial first pass metabolism. aceclofenac is available either in oral form (tablet) or in topical form (gel).

Upstream & downstream products

Upstream raw materials

Benzyl 2-bromoacetateAceclofenac tert-butyl esterHydrochloric acidAcetic anhydrideAcetic acid

Suppliers100 total

北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
衢州润东化工有限公司0570-8789886 18892685668 · [email protected]
Shanghai Biolang Biotechnology Co., Ltd.+86-15970428662 +86-13397199602 · [email protected]
河北展药生物科技有限公司15369953316 +8615369953316 · [email protected]
爱斯特(成都)生物制药股份有限公司+86-28-85122536 85324413 · [email protected]
Jai Radhe Sales+(91)-(79)-26431096/65255722 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
Syntechem Co.,Ltd[email protected]
上海迈瑞尔生化科技有限公司4006356688 18621169109 · [email protected]
太原市瑞和丰科贸有限公司+86 351 7031519 · [email protected]
安耐吉化学&3A(安徽泽升科技股份有限公司)400-0056266 · [email protected]
上海柯维化学技术有限公司021-64609169 18901607656 · [email protected]
上海相辉医药科技有限公司13761987713 · [email protected]
嘉兴市艾森化工有限公司0573-85285100 18627885956 · [email protected]
Pure Chemistry Scientific Inc.001-857-928-2050 or 1-888-588-9418 · [email protected]
上海泰坦科技股份有限公司4006009262 13023226327 · [email protected]
MedChemexpress LLC021-58955995 · [email protected]
孝感深远化工有限公司15527621225; 15527621225 · [email protected]
斯百全化学(上海)有限公司021-021-021-67601398-809-809-809 15221380277 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
上海明褀化学有限公司86-21-60936353
TCI AMERICA800-4238616 · [email protected]
TOKYO CHEMICAL INDUSTRY CO., LTD.03-36680489 · [email protected]
TCI Europe320-37350700 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
广州爱纯医药科技有限公司020-39119399 18927568969 · [email protected]
南京生利德生物科技有限公司025-57798810 18652991625 · [email protected]
山东博洛达生物科技有限公司0531-68651502 · [email protected]
湖北威德利化学试剂有限公司186-02735115 18602735115 · [email protected]
Cato Research Chemicals Inc.020-81960175 · [email protected]
湖北鑫源顺医药化工有限公司13971561712, 13995564702, 027-50664929 · [email protected]
上海湄水化工科技有限公司021-60549325 18616193163
上海将来实业股份有限公司021-61552785 · [email protected]
HBCChem, Inc.+1-510-219-6317 · [email protected]
上海笛柏生物科技有限公司400-008-9730,021-54359730 400-008-9730 · [email protected]
四川省维克奇生物科技有限公司028-81700200 18116577057 · [email protected]
成都零六生物科技有限公司400-1166-196 13458535857 · [email protected]
雷丁试剂0510-85629785 18013409632 · [email protected]
上海创赛科技有限公司400-6087598 15021221957 · [email protected]
上海御略医药科技有限公司021-60345187 13671753212 · [email protected]
上海乾劲化工科技有限公司021-20900665 17321230821 · [email protected]
上海孚一生物科技有限公司+86 (21) 61124340
凯试(上海)科技有限公司021-50135380 · [email protected]
池州凯隆进出口贸易有限公司[email protected]
Sigma-Aldrich西格玛奥德里奇(上海)贸易有限公司021-61415566 800-8193336 · [email protected]
TargetMol中国(陶术生物)021-021-33632979 15002134094 · [email protected]
Alfa Chemistry1-516-6625404 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
上海皓之翔生物科技有限公司(原上海拓青化工有限公司)526763801 13301653310 · [email protected]
Additional notes · 1 item

DefinitionChEBI: Aceclofenac is a monocarboxylic acid that is the carboxymethyl ester of diclofenac. A non-steroidal anti-inflammatory drug related to diclofenac, it is used in the management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It has a role as an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. It is a monocarboxylic acid, a carboxylic ester, a secondary amino compound, an amino acid and a dichlorobenzene. It derives from a diclofenac.